Literature DB >> 32189610

Safety Considerations for Malaria Volunteer Infection Studies: A Mini-Review.

Anand Odedra1,2, James S McCarthy3,1.   

Abstract

Malaria clinical studies entailing the experimental infection of healthy volunteers with Plasmodium parasites by bites from infected mosquitos, injection of cryopreserved sporozoites, or injection of blood-stage parasites provide valuable information for vaccine and drug development. Success of these studies depends on maintaining safety. In this mini-review, we discuss the safety risks and associated mitigation strategies of these three types of experimental malaria infection. We aimed to inform researchers and regulators who are currently involved in or are planning to establish experimental malaria infection studies in endemic or non-endemic settings.

Entities:  

Mesh:

Year:  2020        PMID: 32189610      PMCID: PMC7204585          DOI: 10.4269/ajtmh.19-0351

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  62 in total

1.  Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers.

Authors:  Meta Roestenberg; Sake J de Vlas; An-Emmie Nieman; Robert W Sauerwein; Cornelus C Hermsen
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

2.  Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.

Authors:  Kirsten E Lyke; Andrew S Ishizuka; Andrea A Berry; Sumana Chakravarty; Adam DeZure; Mary E Enama; Eric R James; Peter F Billingsley; Anusha Gunasekera; Anita Manoj; Minglin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Natasha Kc; Tooba Murshedkar; Floreliz H Mendoza; Ingelise J Gordon; Kathryn L Zephir; LaSonji A Holman; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Jamie G Saunders; Nina M Berkowitz; Barbara J Flynn; Martha C Nason; Lindsay S Garver; Matthew B Laurens; Christopher V Plowe; Thomas L Richie; Barney S Graham; Mario Roederer; B Kim Lee Sim; Julie E Ledgerwood; Stephen L Hoffman; Robert A Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

3.  Plasmodium-infected Anopheles mosquitoes collected in Virginia and Maryland following local transmission of Plasmodium vivax malaria in Loudoun County, Virginia.

Authors:  Leon L Robert; Patricia D Santos-Ciminera; Richard G Andre; George W Schultz; Phillip G Lawyer; Joseph Nigro; Penny Masuoka; Robert A Wirtz; John Neely; David Gaines; Charles E Cannon; Denise Pettit; Carol W Garvey; David Goodfriend; Donald R Roberts
Journal:  J Am Mosq Control Assoc       Date:  2005-06       Impact factor: 0.917

4.  Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study.

Authors:  James S McCarthy; Bryan Smith; Mark Reid; Jonathan Berman; Louise Marquart; Caroline Dobbin; Leanne West; Lisa T Read; Geoff S Dow
Journal:  Clin Infect Dis       Date:  2019-07-18       Impact factor: 9.079

5.  Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.

Authors:  Susanne H Sheehy; Alexandra J Spencer; Alexander D Douglas; B Kim Lee Sim; Rhea J Longley; Nick J Edwards; Ian D Poulton; Domtila Kimani; Andrew R Williams; Nicholas A Anagnostou; Rachel Roberts; Simon Kerridge; Merryn Voysey; Eric R James; Peter F Billingsley; Anusha Gunasekera; Alison M Lawrie; Stephen L Hoffman; Adrian V S Hill
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

6.  Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya.

Authors:  Susanne H Hodgson; Elizabeth Juma; Amina Salim; Charles Magiri; Daniel Njenga; Sassy Molyneux; Patricia Njuguna; Ken Awuondo; Brett Lowe; Peter F Billingsley; Andrew O Cole; Caroline Ogwang; Faith Osier; Roma Chilengi; Stephen L Hoffman; Simon J Draper; Bernhards Ogutu; Kevin Marsh
Journal:  Malar J       Date:  2015-04-28       Impact factor: 2.979

7.  Arthropod Containment Guidelines, Version 3.2.

Authors: 
Journal:  Vector Borne Zoonotic Dis       Date:  2019-01-29       Impact factor: 2.133

8.  Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Authors:  Michele D Spring; James F Cummings; Christian F Ockenhouse; Sheetij Dutta; Randall Reidler; Evelina Angov; Elke Bergmann-Leitner; V Ann Stewart; Stacey Bittner; Laure Juompan; Mark G Kortepeter; Robin Nielsen; Urszula Krzych; Ev Tierney; Lisa A Ware; Megan Dowler; Cornelus C Hermsen; Robert W Sauerwein; Sake J de Vlas; Opokua Ofori-Anyinam; David E Lanar; Jack L Williams; Kent E Kester; Kathryn Tucker; Meng Shi; Elissa Malkin; Carole Long; Carter L Diggs; Lorraine Soisson; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; D Gray Heppner
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

9.  Mosquito Passage Dramatically Changes var Gene Expression in Controlled Human Plasmodium falciparum Infections.

Authors:  Anna Bachmann; Michaela Petter; Ralf Krumkamp; Meral Esen; Jana Held; Judith A M Scholz; Tao Li; B Kim Lee Sim; Stephen L Hoffman; Peter G Kremsner; Benjamin Mordmüller; Michael F Duffy; Egbert Tannich
Journal:  PLoS Pathog       Date:  2016-04-12       Impact factor: 6.823

10.  A bioreactor system for the manufacture of a genetically modified Plasmodium falciparum blood stage malaria cell bank for use in a clinical trial.

Authors:  Rebecca Pawliw; Rebecca Farrow; Silvana Sekuloski; Helen Jennings; Julie Healer; Thuan Phuong; Pri Sathe; Cielo Pasay; Krystal Evans; Alan F Cowman; Louis Schofield; Nanhua Chen; James McCarthy; Katharine Trenholme
Journal:  Malar J       Date:  2018-08-06       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.